Gilead Sciences | GILD - Fremdkapital

Aktienkurs
129.25
Täglich Wechseln
1.50 1.17%
Monatlich
-5.20%
Jährlich
24.03%
Q2 Prognose
127.61




Fremdkapital Veränderung Datum
AbbVie USD 62.97B 12M 2025-09
Agios Pharmaceuticals USD 1.06M 0 2022-09
ALKERMES USD 285.82M 639K 2024-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Amgen USD 50B 2.43B 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Gilead Sciences USD 22.13B 6M 2025-12
GlaxoSmithKline GBP 14.71B 186M 2025-12
Glaxosmithkline GBP 19.82B 203.13M 2025-12
Incyte USD 29.41M 785K 2026-03
J&J USD 37.53B 1.91B 2026-03
Merck USD 39.97B 6B 2025-09
Moderna USD 610M 584M 2025-12
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 13.84B 1.88B 2026-03
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
United Therapeutics USD 100M 100M 2024-06
Vertex Pharmaceuticals USD 111.4M 1.4M 2025-03